SMO ClinPlus 普蕊斯
4 significant filings since 1 Jun 2026: 3 on major holder selling and 1 on dividend. The latest, on 24 Aug 2026: 关于公司股东减持股份预披露公告.
自 1 Jun 2026 起有 4 份重大公告：major holder selling 3 份、dividend 1 份。最新一份（24 Aug 2026）：关于公司股东减持股份预披露公告。
Price History 价格走势
1,063 trading days 个交易日 · High 最高 ¥82.72 · Low 最低 ¥23.04The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 6 May 2025 | 长城国瑞证券 | 胡晨曦 | Buy 买入 | ▼ | Outperform 增持 |
| 30 Apr 2024 | 长城国瑞证券 | 胡晨曦 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 胡光怿,杜向阳 | Unrated | 15 Jul 2026 | 1 | — |
| 长城国瑞证券 | 胡晨曦,魏钰琪 | Outperform 增持 | 9 May 2026 | 1 | — |
| 中邮证券 | 盛丽华,辛家齐 | Buy 买入 | 7 May 2026 | 2 | — |
| 太平洋 | 周豫,张崴 | Buy 买入 | 1 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 5 reports. 每行为该券商近十二个月的最新研报；5 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。